keyword
MENU ▼
Read by QxMD icon Read
search

Her2 positive, hormone positive

keyword
https://www.readbyqxmd.com/read/28916978/tumor-biology-predicts-pathologic-complete-response-to-neoadjuvant-chemotherapy-in-patients-presenting-with-locally-advanced-breast-cancer
#1
Lori F Gentile, George Plitas, Emily C Zabor, Michelle Stempel, Monica Morrow, Andrea V Barrio
BACKGROUND: Neoadjuvant chemotherapy (NAC) is used to convert patients with inoperable locally advanced breast cancer (LABC) to operability, but has not traditionally been used to avoid mastectomy or axillary dissection in this subset. OBJECTIVE: The purpose of this study was to determine the rates of pathologic complete response (pCR) in LABC patients, and identify factors predictive of pCR to determine if responding patients might be suitable for limited surgery...
September 15, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28916815/programmed-death-ligand-1-pd-l1-expression-in-tumour-cell-and-tumour-infiltrating-lymphocytes-of-her2-positive-breast-cancer-and-its-prognostic-value
#2
Ahrong Kim, So Jeong Lee, Young Keum Kim, Won Young Park, Do Youn Park, Jee Yeon Kim, Chang Hun Lee, Gyungyub Gong, Gi Yeong Huh, Kyung Un Choi
Immunotherapy targeting PD-1/PD-L1 axis showed benefits in cancer. Prognostic significance of tumour infiltrating lymphocytes (TILs) has been determined. We evaluated PD-L1 protein expression in tumour cells and TILs, PD-L1 mRNA level and various histopathologic factors including TILs using 167 formalin-fixed paraffin embedded tissues and 39 fresh tissue of HER2-positive breast cancer. TILs level and PD-L1 expression in tumour cells and TILs were significantly correlated one another. PD-L1 positivity in tumour cells was associated with high histologic grade and high TILs level (p < 0...
September 15, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28911092/concurrent-and-sequential-initiation-of-ovarian-function-suppression-with-chemotherapy-in-premenopausal-women-with-endocrine-responsive-early-breast-cancer-an-exploratory-analysis-of-text-and-soft
#3
M M Regan, B A Walley, P A Francis, G F Fleming, I Láng, H L Gómez, M Colleoni, C Tondini, G Pinotti, M Salim, S Spazzapan, V Parmar, T Ruhstaller, E A Abdi, R D Gelber, A S Coates, A Goldhirsch, O Pagani
Background: Recent breast cancer treatment guidelines recommend that higher-risk premenopausal patients should receive ovarian function suppression (OFS) as part of adjuvant endocrine therapy. If chemotherapy is also given, it is uncertain whether to select concurrent or sequential OFS initiation. Design and methods: We analyzed 1872 patients enrolled in the randomized phase III TEXT and SOFT trials who received adjuvant chemotherapy for hormone receptor-positive, HER2-negative breast cancer and upon randomization to an OFS-containing adjuvant endocrine therapy, initiated gonadotropin-releasing-hormone-agonist triptorelin...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28903441/loss-of-steroid-hormone-receptors-is-common-in-malignant-pleural-and-peritoneal-effusions-of-breast-cancer-patients-treated-with-endocrine-therapy
#4
Willemijne A M E Schrijver, Karianne Schuurman, Annelot van Rossum, Ton Peeters, Natalie Ter Hoeve, Wilbert Zwart, Paul J van Diest, Cathy B Moelans
Discordance in estrogen receptor alpha (ERα), progesterone receptor (PR), androgen receptor (AR) and human epidermal growth factor receptor 2 (HER2) status between primary breast cancers and solid distant metastases ("conversion") has been reported previously. Even though metastatic spread to the peritoneal and pleural cavities occurs frequently and is associated with high mortality, the rate of receptor conversion and the prognostic implications thereof remain elusive. We therefore determined receptor conversion in 91 effusion metastases (78 pleural, 13 peritoneal effusions) of 69 patients by immunohistochemistry (IHC) and in situ hybridization...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28900476/breast-cancer-in-angola-molecular-subtypes-a-first-glance
#5
Fernando Miguel, Lygia Vieira Lopes, Eduardo Ferreira, Emília Ribas, Alexis Fuentes Pelaez, Conceição Leal, Teresina Amaro, Paula Lopes, Cristina Mendes Santos, Carlos Lopes, Lúcio Lara Santos
PURPOSE: The aim of this study was to investigate the breast cancer (BC) molecular subtypes according to its surrogate immunohistochemistry (IHC) markers. We conducted a preliminary study, to correlate the clinical pathological profiles and molecular subtypes of breast cancer in Luanda, Angola. METHODS: From January 2011 to 30 December 2014, 140 consecutive cases of microscopically confirmed invasive breast carcinoma were classified regarding histology and IHC (ER, PR, HER2, and Ki-67)...
2017: Ecancermedicalscience
https://www.readbyqxmd.com/read/28877230/decision-impact-and-feasibility-of-different-asco-recommended-biomarkers-in-early-breast-cancer-prospective-comparison-of-molecular-marker-endopredict-and-protein-marker-upa-pai-1
#6
Johannes Ettl, Evelyn Klein, Alexander Hapfelmeier, Kirsten Grosse Lackmann, Stefan Paepke, Christoph Petry, Katja Specht, Laura Wolff, Heinz Höfler, Marion Kiechle
BACKGROUND: Adjuvant therapy decisions in early breast cancer are based on accurate risk assessment. Urokinase plasminogen activator (uPA) and plaminogen activator inhibitor-1 (PAI-1) have been the first biomarkers in hormone receptor (HR) positive breast cancer to reach highest level of evidence. The EndoPredict test (EPclin) combines gene expression information with nodal status and tumor size. The aim of this prospective study was to compare uPA/PAI-1 and EPclin as prognostic biomarkers with regard to feasibility, risk stratification and impact on adjuvant therapy recommendation...
2017: PloS One
https://www.readbyqxmd.com/read/28875097/sustained-long-term-maintenance-of-remission-with-single-agent-veliparib-in-recurrent-triple-negative-breast-cancer
#7
Karthik Kota, Shannon Puhalla
Triple-negative breast cancers (TNBC) have poorer outcomes than hormone positive or human epidermal growth factor receptor 2 (HER2)-positive breast cancers, with chemotherapy being the usual standard of care. Veliparib, a poly ADP-ribose polymerase (PARP) inhibitor, has been studied in both breast cancer susceptibility genes 1 and 2 (BRCA)-mutation related and sporadic cancers as a single agent and in combination with chemotherapy. Here, we describe a patient whose metastatic recurrence of TNBC was treated with combination chemotherapy and veliparib followed by maintenance single-therapy veliparib...
July 4, 2017: Curēus
https://www.readbyqxmd.com/read/28874120/the-association-between-smoking-and-breast-cancer-characteristics-and-outcome
#8
Hadar Goldvaser, Omer Gal, Shulamith Rizel, Daniel Hendler, Victoria Neiman, Tzippy Shochat, Aaron Sulkes, Baruch Brenner, Rinat Yerushalmi
BACKGROUND: Smoking is associated with an increased incidence of hormone receptor positive breast cancer. Data regarding worse breast cancer outcome in smokers are accumulating. Current literature regarding the impact of smoking on breast cancer characteristics is limited. We evaluated the impact of smoking on breast cancer characteristics and outcome. METHODS: This was a retrospective single center study. All women diagnosed from 4/2005 through 3/2012 and treated in our institute for early, estrogen receptor positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer, whose tumors were sent for Oncotype DX analysis were included...
September 6, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28869790/evaluating-the-role-of-magnetic-resonance-imaging-post-neoadjuvant-therapy-for-breast-cancer-in-the-neonab-trial
#9
Caitlin Murphy, Violet Mukaro, Robert Tobler, Rebecca Asher, Emma Gibbs, Linda West, Bruno Giuffre, Sally Baron-Hay, Mustafa Khasraw
BACKGROUND: Magnetic Resonance Imaging (MRI) accuracy after neoadjuvant systemic therapy (NST) for breast cancer varies according to hormone receptor (HR), human epidermal growth factor receptor type-2 (HER2) subtype and Ki67 proliferation index. Whether MRI accuracy varies by genomic signatures is unknown. We examined accuracy of MRI in the NEONAB trial (Clinicaltrials.gov #: NCT01830244). METHODS: Patients with stage II-III breast cancer received sequential epirubicin, cyclophosphamide and nab-paclitaxel and trastuzumab if HER2+...
September 4, 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/28863313/duration-of-adjuvant-trastuzumab-in-her2-positive-breast-cancer-overall-and-disease-free-survival-results-from-meta-analyses-of-randomized-controlled-trials
#10
REVIEW
Bishal Gyawali, Saroj Niraula
BACKGROUND: One year of trastuzumab, chosen empirically, improves survival of women with early-stage, HER2-positive breast cancer but also adds substantially to cost, toxicity, and inconvenience. Longer treatment does not improve outcomes, but potentiates toxicities. METHODS: Medline, Embase, and major conference proceedings were searched systematically in June 2017 to identify Randomized Controlled Trials (RCTs) comparing one year versus shorter durations of trastuzumab in adjuvant treatment of breast cancer...
August 19, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28859290/racial-differences-in-pam50-subtypes-in-the-carolina-breast-cancer-study
#11
Melissa A Troester, Xuezheng Sun, Emma H Allott, Joseph Geradts, Stephanie M Cohen, Chiu-Kit Tse, Erin L Kirk, Leigh B Thorne, Michelle Mathews, Yan Li, Zhiyuan Hu, Whitney R Robinson, Katherine A Hoadley, Olufunmilayo I Olopade, Katherine E Reeder-Hayes, H Shelton Earp, Andrew F Olshan, Lisa A Carey, Charles M Perou
Background: African American breast cancer patients have lower frequency of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative disease and higher subtype-specific mortality. Racial differences in molecular subtype within clinically defined subgroups are not well understood. Methods: Using data and biospecimens from the population-based Carolina Breast Cancer Study (CBCS) Phase 3 (2008-2013), we classified 980 invasive breast cancers using RNA expression-based PAM50 subtype and recurrence (ROR) score that reflects proliferation and tumor size...
February 1, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28851309/differences-in-elongation-of-very-long-chain-fatty-acids-and-fatty-acid-metabolism-between-triple-negative-and-hormone-receptor-positive-breast-cancer
#12
Yuji Yamashita, Shin Nishiumi, Seishi Kono, Shintaro Takao, Takeshi Azuma, Masaru Yoshida
BACKGROUND: Triple-negative breast cancer (TN) is more aggressive than other subtypes of breast cancer and has a lower survival rate. Furthermore, detailed biological information about the disease is lacking. This study investigated characteristics of metabolic pathways in TN. METHODS: We performed the metabolome analysis of 74 breast cancer tissues and the corresponding normal breast tissues using LC/MS. Furthermore, we classified the breast cancer tissues into ER-positive, PgR-positive, HER2-negative breast cancer (EP+H-) and TN, and then the differences in their metabolic pathways were investigated...
August 29, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28830795/indications-for-postmastectomy-radiation-after-neoadjuvant-chemotherapy-in-ypn0-and-ypn1-3-axillary-node-positive-women
#13
Barbara Fowble, Abhishek Keshav Jairam, Frederick Wang, Anne Peled, Michael Alvarado, Cheryl Ewing, Laura Esserman, Catherine Park, Ann Lazar
INTRODUCTION: Downstaging with neoadjuvant chemotherapy (NAC) might obscure indications for postmastectomy radiation (PMRT). The degree of downstaging that results in local-regional recurrence (LRR) rates low enough to omit PMRT remains controversial. We examined the rate of LRR in women who received NAC who underwent mastectomy without PMRT. PATIENTS AND METHODS: Between 2004 and 2013, 81 women with stage I to IIIA breast cancer had NAC and mastectomy; 48 patients (59%) were clinical N0 and 33 patients (41%) were clinical N1; median age was 45 years; 33 patients (41%) had hormone receptor-positive (HR(+))HER2(-), 21 patients (26%) HR(+)HER2(+), 19 patients (23%) HR(-) HER2(-), and 7 patients (9%) HR(-)HER2(+) disease...
August 1, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28816986/efficacy-and-safety-of-endocrine-monotherapy-as-first-line-treatment-for-hormone-sensitive-advanced-breast-cancer-a-network-meta-analysis
#14
Jingwen Zhang, Yanhong Huang, Changyi Wang, Yuanfang He, Shukai Zheng, Kusheng Wu
BACKGROUND: Endocrine therapy was recommended as the preferred first-line treatment for hormone receptor-positive (HR+, i.e., ER+ and/or PgR+), human epidermal growth factor receptor-2-negative (HER2-) postmenopausal advanced breast cancer (ABC), but which endocrine monotherapy is optimal lacks consensus. We aimed to identify the optimal endocrine monotherapy with a network meta-analysis. METHODS: We performed a network meta-analysis for a comprehensive analysis of 6 first-line endocrine monotherapies (letrozole, anastrozole, exemestane, tamoxifen, fulvestrant 250 mg and 500 mg) for HR+ HER2- metastatic or locally advanced breast cancer in postmenopausal patients...
August 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28815327/molecular-characterization-and-heterogeneity-of-circulating-tumor-cells-in-breast-cancer
#15
Anna Jakabova, Zuzana Bielcikova, Eliska Pospisilova, Rafal Matkowski, Bartlomiej Szynglarewicz, Urszula Staszek-Szewczyk, Milada Zemanova, Lubos Petruzelka, Petra Eliasova, Katarina Kolostova, Vladimir Bobek
INTRODUCTION: This study analyzes peripheral blood samples from breast cancer (BC) patients. CTCs from peripheral blood were enriched by size-based separation and were then cultivated in vitro. The primary aim of this study was to demonstrate the antigen independent CTC separation method with high CTC recovery. Subsequently, CTCs enriched several times during the treatment were characterized molecularly. METHODS: Patients with different stages of BC (N = 167) were included into the study...
August 16, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28811185/the-effect-of-receptor-status-on-mastectomy-and-contralateral-prophylactic-mastectomy-rates-in-early-stage-invasive-breast-carcinoma
#16
Sunil W Dutta, Daniel M Trifiletti, Surbhi Grover, Kara D Romano, Einsley-Marie Janowski, Shayna L Showalter
BACKGROUND: There is an established relationship between hormone receptor (HR; estrogen and/or progesterone receptors) status, HER2 status, and locoregional recurrence. The purpose of this study was to analyze how HR and HER2 receptor status have influenced the surgical management trends among patients with early stage breast cancer. PATIENTS AND METHODS: The National Cancer Database was queried for patients with cT1 to cT3, cN0, and cM0 breast carcinoma from 2004 to 2012...
June 29, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28808484/er%C3%AE-and-er%C3%AE-co-expression-an-indicator-of-aggressive-tumors-and-hormonal-sensitivity
#17
Mohamed Oueslati, Ilhem Bittaieb, Nadia Sassi, Awatef Ben Jemaa, Amor Gamoudi, Khaled Rahal, Ridha Oueslati
The estrogen receptors (ERs) ERα and ERβ are important factors in breast cancer progression. Nevertheless, the molecular interplay between ERα and ERβ and its clinical significance in breast cancer is controversial. The establishment of a clear association is required; therefore, the current study analyzed the expression patterns of ERα and ERβ in 32 breast tumor tissues using reverse transcription-quantitative polymerase chain reaction. Furthermore, human epidermal growth factor receptor 2 (HER2) and the Ki-67 status were detected by immunohistochemistry...
August 2017: Oncology Letters
https://www.readbyqxmd.com/read/28798006/breast-adenoid-cystic-carcinoma-a-rare-case-report-and-review-of-the-literature
#18
Lamiae El Amarti, Hanan Raiss, Mohamed Layachi, Salif Baldé, Hamza Ettahri, Ibrahim Elghissassi, Hind Mrabti, Hassan Errihani
BACKGROUND: Primary adenoid cystic carcinoma (ACC) of the breast is a rare subtype of invasive breast cancer. It has a particular interest because of its excellent prognosis conversely to other triple-negative breast cancers that are associated with poor prognosis. The place of chemotherapy and radiotherapy remains controversial and there is no consensus on optimal management of the ACC of the breast. CASE REPORT: A 50-year-old woman, presented with a palpable right breast lump...
May 2017: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/28795861/lnc00673-errlr01-is-a-prognostic-indicator-of-overall-survival-in-breast-cancer
#19
Ubaidat Abdul-Rahman, Balázs Gyoörffy, Brian D Adams
LncRNAs are novel noncoding RNAs involved in the epigenetic regulation of gene expression by recruiting ribonucleoprotein complexes to specific genomic loci to initiate histone methylation and/or other chromatin modifications. LncRNAs themselves function as tumor suppressors or oncogenes, depending on the gene regulatory networks they govern. We identified lnc00673 (ERRLR01) as a marker of overall survival (OS) in breast cancer patients. Specifically, ERRLR01 levels were elevated in triple-negative breast cancer (TNBC) as compared to Luminal- A, Luminal-B, and HER2 breast cancer subtypes...
August 10, 2017: Transcription
https://www.readbyqxmd.com/read/28779904/ixabepilone-and-carboplatin-for-hormone-receptor-positive-her2-neu-negative-and-triple-negative-metastatic-breast-cancer
#20
Cynthia Osborne, Jagathi D Challagalla, Charles F Eisenbeis, Frankie Ann Holmes, Marcus A Neubauer, Nicholas W Koutrelakos, Carlos A Taboada, Sasha J Vukelja, Sharon T Wilks, Mary Ann Allison, Praveen Reddy, Scot Sedlacek, Yunfei Wang, Lina Asmar, Joyce O'Shaughnessy
BACKGROUND: Hormonal therapies and single-agent sequential chemotherapeutic regimens are the standards of care for HER2(-) metastatic breast cancer (MBC). However, treating patients with hormone-refractory and triple negative (TN) MBC remains challenging. We report the results of combined ixabepilone and carboplatin in a single-arm phase II trial. PATIENTS AND METHODS: In the present prospective analysis of hormone receptor-positive (HR(+))/HER2(-) and TN MBC cohorts, patients could have received 0 to 2 chemotherapy regimens for MBC before enrollment...
July 10, 2017: Clinical Breast Cancer
keyword
keyword
21972
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"